Table 1.
Baseline characteristics of the 108 patients included in the study.
| Number | (%) | |
|---|---|---|
| Age, years | ||
| Median (IQR) | 69 (58.3–76.8) | |
| Sex | ||
| Male | 72 | 66.7 |
| Primary tumor site | ||
| Colon–rectum | 14 | 13.0 |
| Lung | 13 | 12.0 |
| Stomach | 13 | 12.0 |
| Pancreas | 11 | 10.2 |
| Pharynx | 5 | 4.6 |
| Breast | 5 | 4.6 |
| Kidney | 5 | 4.6 |
| Uterus | 5 | 4.6 |
| Prostate | 4 | 3.7 |
| Other | 33 | 30.6 |
| Extent of disease | ||
| Metastatic | 107 | 99.1 |
| Local | 1 | 0.9 |
| Metastatic locations | ||
| Lymph node | 86 | 79.6 |
| Liver | 45 | 41.7 |
| Bone | 40 | 37.0 |
| Lung | 32 | 29.6 |
| Peritoneal | 27 | 25.0 |
| History of anticancer treatment | ||
| Chemotherapy and/or biologic treatment | 87 | 80.6 |
| Surgery | 58 | 53.7 |
| Radiotherapy | 30 | 27.8 |
| None | 12 | 11.1 |
| ECOG Performance Status Score | ||
| 1 | 9 | 8.3 |
| 2 | 35 | 32.4 |
| 3 | 48 | 44.4 |
| 4 | 16 | 14.8 |
| Survival time, days | ||
| Median (IQR) | 33 (14.3–62) | |
| Mean (SD) | 41.9 (33.4) |
ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; SD, standard deviation.